Dr. Sanger, meet Mr. Moore
نویسندگان
چکیده
منابع مشابه
Dr Jekyll and Mr C
Jekyll is a high level programming language that can be translated losslessly to and from human readable, human editable C. This makes it possible to maintain Jekyll and C versions of the same file, with any changes made to one file being automatically reflected into the other. By being losslessly inter-translatable with C, Jekyll reduces the switching costs normally associated with moving to a...
متن کاملDr Cabot and Mr Hyde
1 Neuroscience Research Institute, University of California at Santa Barbara, Santa Barbara, California, United States of America, 2 Department of Molecular, Cellular and Developmental Biology, University of California at Santa Barbara, Santa Barbara, California, United States of America, 3 Kavli Institute of Theoretical Physics, University of California at Santa Barbara, Santa Barbara, Califor...
متن کاملAn appreciation of Dr Michael Moore, Editor, BJC, 1979-1988
Now that the transition to the new editorial team of the BJC is complete, it is appropriate to pay tribute to the now ex-editor, Michael Moore. Michael left the Paterson Institute, where he had been head of the immunology group for 15 years, to take up a post in industry in July 1988. I do not recall it now, but he says that, when he told me that he wished to resign as editor, I responded by sa...
متن کاملNice to meet you, Mr. GFR!
Teleologically speaking kidney’s function is designed to maintain life parameters as close as possible to the normal level. Clearance is a tool to compare renal function among different individuals independently on urine flow, body size and solute concentration in blood. Since the tubulus manipulates the glomerular filtrate composition, for the computation of clearance as a surrogate of GFR, we...
متن کاملTamoxifen: Dr. Jekyll and Mr. Hyde?
Without regard to patient selection, other than the eligibility requirements for entry into the studies, worldwide overviews of prospective clinical trials demonstrate that adjuvant tamoxifen reduces the annual odds of death for women with invasive breast cancer by approximately 15% over 10–15 years (1). These data raise the provocative question: Should all patients with invasive breast cancer ...
متن کاملذخیره در منابع من
با ذخیره ی این منبع در منابع من، دسترسی به آن را برای استفاده های بعدی آسان تر کنید
ژورنال
عنوان ژورنال: BioEssays
سال: 2011
ISSN: 0265-9247
DOI: 10.1002/bies.201100146